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Abbreviations 
Aβ: amyloid beta peptide; AD: Alzheimer’s disease; ALS: amyotrophic lateral sclerosis; APP: 
Amyloid precursor protein; CNS: central nervous system; EAAT: excitatory amino acid 
transporter; GFAP: glial fibrillary acidic protein; GABA: γ-aminobutyric acid; GAT: γ-
aminobutyric acid transporter; GLUT: glucose transporter; GlyT: glycine transporter; 5-HT: 5-
hydroxytryptamine, serotonin; MCT: monocarboxylic acid transporters; NMDA: N-methyl-D-
aspartate; SERT: serotonin transporter; SGLT: sodium-glucose symporter; S100B: S100 
calcium-binding protein B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Abstract 
Astrocytes play a fundamental role in maintaining the health and function of the central 
nervous system. Increasing evidence indicates that astrocytes undergo both cellular and 
molecular changes at an early stage in neurological diseases, including Alzheimer’s disease. 
These changes may reflect a change from a neuroprotective to a neurotoxic phenotype. Given 
the lack of current disease modifying therapies for Alzheimer’s disease, astrocytes have 
become an interesting and viable target for therapeutic intervention. The astrocyte transport 
system covers a diverse array of proteins involved in metabolic support, neurotransmission 
and synaptic architecture. Therefore, specific targeting of individual transporter families has 
the potential to suppress neurodegeneration, a characteristic hallmark of Alzheimer’s disease. 
A small number of the four hundred transporter superfamilies’ are expressed in astrocytes, 
with evidence highlighting a fraction of these are implicated in Alzheimer’s disease. Here we 
review the current evidence for six astrocytic transporter subfamilies involved in Alzheimer’s 
disease, as reported in both animal and human studies. This review confirms that astrocytes 
are indeed a viable target, highlights the complexities of studying astrocytes and provides 
future directives to exploit the potential of astrocytes in tackling Alzheimer’s disease. 
 
 
 
 
 
 
 
 
4 
 
Introduction  
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterised by 
deposition of amyloid plaques, neurofibrillary tangle formation, synaptic loss and neuronal cell 
death (1). Whilst understanding of AD pathology has been predominantly ‘neurocentric’, 
recent advances in techniques and experimental models provide some valuable insights into 
astrocytes in AD pathogenesis (2,3). Astrocytes are present in the nervous system in 
approximately equal numbers to neurons (4), and have intimate physical connections with 
synapses and blood vessels. An appreciation of the diverse range of roles they play has 
gathered pace in the last 20 years (5,6). Far from being passive bystanders as once thought, 
strong evidence highlights astrocytes as dynamic components of CNS physiology and 
pathophysiology. For example, through cellular connections with brain endothelial cells, 
astrocytes regulate neurovascular coupling which ensures activity-dependent metabolite 
supply to neurons, and as cellular partners of neurons at synapses, astrocytes regulate 
potassium ions, hydrogen ions and take up neurotransmitters to influence synaptic signalling 
and plasticity (7–9).  Alteration in astrocyte functions could contribute to AD processes; 
namely, synaptic loss, neurodegeneration, amyloid deposition and tangle formation. Indeed, 
it is found that regional specificity, initially considered to be a neuronal phenomenon, also 
applies to astrocytes(10,11).  
While there is no or little astrocyte loss, both human post-mortem and animal studies show 
there is a distinct change in astrocyte morphology and physiology associated with pathology 
(12–14). Research to date indicates that the number of astrocytes remains consistent in post-
mortem brains as well as in animal models of AD (overexpression of Aβ) as determined by 
immunostaining with available astrocytic markers (GFAP, S100B and glutamine synthetase) 
(15–17). This change in phenotype is most often reported as an increase in astrocyte 
reactivity, as visualised by increased protein levels of the intermediate filament, glial fibrillary 
acid protein (GFAP). Increases in GFAP coincide with astrocyte hypertrophy and changes in 
morphology (18). While the number of reactive astrocytes correlates well with disease state in 
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animal models (18,19), it is important to note that human studies have revealed increased 
astrocyte reactivity is not only associated with disease, but also reflects ageing (12). In several 
transgenic mouse models of AD; astrocyte reactivity occurs before detectable amyloid plaque 
deposition (20,21) and therefore may be regarded an early marker of pathology (Figure 1). 
Currently there is debate on whether reactive astrocytes contribute to neurodegeneration, or 
are indeed neuroprotective (22). Although it is usually GFAP which is measured, astrocyte 
reactivity is associated with a wealth of molecular changes which are incompletely 
characterised (18), and characterisation of these molecular changes can provide insight into 
disease process and potential therapeutic targets. 
Astrocyte functional capacity is a consequence of a complex transcriptome (23,24), and 
astrocytes express numerous receptors, transporters and signalling molecules which allow 
them to regulate CNS homeostasis, provide neuroprotection, and contribute to 
neurodegeneration.  Amongst the proteins pivotal in the maintenance of cellular and system 
homeostasis are transporter proteins, with over four hundred superfamilies’ (25). Astrocytes 
express a variety of transporters, with subfamilies and splice variants adding to their diversity 
(26–28). With a lack of AD-modifying treatments and an urgent need for new molecular targets 
to enter the discovery pipeline, astrocytic transporters provide an avenue for further research 
and development. Here we review evidence for the modulation of astrocyte transporters in AD 
and the implications for future treatment opportunities. Transporters include a diverse group 
of protein families with numerous members and a suitably diverse nomenclature. The rich 
diversity is evident in the topology of the transporters, with highly variable regions connecting 
transmembrane domains (Figure 2). For the purposes of this review, we have used the 
IUPHAR transporter nomenclature (29). A survey of the literature1 revealed several families 
                                               
1 The authors restricted their search to PubMed using search terms: ‘astrocyte and Alzheimer’s 
disease’, ‘astrocyte transporters and Alzheimer’s disease’. Phrases combining Alzheimer’s disease 
and individual transporters, for example, ‘EAAT2 and Alzheimer’s disease’ were also included in the 
search.  
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that have been implicated in AD pathology (Table 1) and some of the major families are 
discussed below. 
1. SLC1 Amino acid transporters  
The SLC1 amino acid transporter family comprises five high affinity glutamate (SLC1A1-3 and 
6-7) and two neutral amino acid transporters (SLC1A4,5) with regional and cell type specific 
expression throughout the CNS (30). Glutamate transporters are predicted to contain eight 
transmembrane domains with two membrane re-entrant loops, and exist as homotrimers (see 
Figure 2A; 31). 
The glutamate transporters regulate glutamate homeostasis at both synaptic and 
extrasynaptic sites through active uptake of glutamate. Cellular uptake of glutamate is coupled 
with three Na+ and one H+ and counter transports one K+ (32). This process is secondary-
active transport, as glutamate uptake does not directly involve ATP catabolism but is instead 
dependent on ionic gradients generated by ATP-dependent pumps, in particular Na+/K+ 
ATPase (see section 5). It is well established that an important  function of these transporters 
is to prevent glutamate-induced excitotoxicity at the synapse (Figure 3), believed to be 
causative in neurodegeneration (33). Given this pivotal role, these proteins have been the 
focus of numerous studies of neurodegeneration (e.g. 32–34) and there is a wealth of data 
available with respect to their modulation in AD pathology. 
EAAT2 (SLC1A2; rat GLT-1) is a transmembrane protein predominantly expressed in 
astrocytes and responsible for approximately 95% of all L-glutamate uptake in the CNS 
(30,37,38). Along with the uptake of glutamate from the synaptic cleft, EAAT2 is an important 
component of the glutamate:glutamine cycle (39,40) involved in the detoxification of 
glutamatergic signalling. EAAT1 (SLC1A3; rat GLAST) is also expressed at the membrane of 
astrocytes and mediates around 5% of the total glutamate transport in the adult CNS (41). In 
relation to AD, these astrocytic transporters are most important given their contribution to total 
glutamate uptake and their predominant expression in brain regions susceptible to AD 
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pathology (42). Arguably the most important of these transporters is EAAT2; indeed, the small 
contribution of EAAT1 to total glutamate uptake has left its role in neurodegenerative diseases, 
particularly AD, largely unknown. 
Mouse models have been a rich source of information with regards AD pathology, but provide 
conflicting data regarding the role and regulation of glutamate transporters. In terms of mouse 
AD models (which overexpress Aβ but do not recapitulate all the pathological features in 
human AD), there is a mixed picture of glutamate transporter alterations. The human amyloid 
precursor protein (APP; hAPP695 (V642I)/APP/Ld) model (43) showed no significant changes 
in EAAT2 or EAAT3 mRNA levels between genotypes; however transgenic animals displayed 
reduced Bmax and KD for [3H] D-aspartate uptake along with significantly decreased EAAT2 
and EAAT1 protein levels as analysed by immunohistochemistry (44). In the APP/PS1 model 
(45), both EAAT2 and synaptophysin protein levels do not change over the lifetime of these 
mice. To further understand a role for EAAT2 in regulating the progression of AD pathology, 
APP/PS1 mice heterozygous for EAAT2 (EAAT2het/APP/PS1) were generated. While long 
term deficits (9 months) in cognition and Aβ load where comparable to wild type mice, there 
was evidence of early deficits in memory tasks and Aβ load at 6 months for the heterozygous 
mouse (46).  In another APP transgenic mouse (APP23 mice) EAAT1 and EAAT2 protein 
levels in both the cortex and hippocampus show an age dependent decrease which preceded 
amyloid plaque deposition and gliosis (47). These studies suggest that loss of the EAAT 
protein renders the brain more vulnerable to neurological insults, including Aβ production.   
The triple transgenic (3xTg-AD) mouse (48) shows no changes in cortical EAAT2 expression 
or distribution (49). This contrasts with the report by Zumkehr et al. (2015) which highlighted 
significant decreases in hippocampal EAAT2 protein and mRNA in a disease dependent 
manner (50). The contrast in observations may highlight regional deficits in EAAT2 (cortical 
vs hippocampal) or approaches to qualitative analysis. From a therapeutic stand point, 
increasing levels of EAAT2 through chronic administration of ceftriaxone restored cognitive 
deficits without impact on the amyloid load (50).  
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Given that AD is a human disease, human tissue remains the most insightful as to monitoring 
pathological changes. The findings from mouse models are in contrast to human data (see 
below) and highlights the complexity of sporadic human AD and also questions the relevance 
of mouse models of AD (51). Radiolabelling and immunohistochemical techniques provided 
initial insight into changes in EAAT protein levels and activity in post-mortem human tissue. 
An early study looked at EAAT2 substrate uptake and reported an AD-related decrease of 
around 30% in aspartate uptake (52). This study highlighted that a functional deficit in EAAT2 
may underlie synaptotoxic elements of AD pathology. Subsequent studies have looked at 
biochemical changes in EAAT2 and reported a decrease in EAAT2 protein levels within AD 
brains (12,53–56). Studies have suggested a link between EAAT2 reduction and APP 
processing (56), Braak stage progression in AD (12), amyloid plaque deposition (55)  and  
cognitive impairment (57). However there are conflicting reports as to changes in EAAT2 
mRNA levels observed in AD brains; studies have highlighted no change (56) or a decrease 
(54,55) in EAAT2 mRNA in AD tissue compared to controls. Therefore, evidence exists for 
both pre and post transcriptional regulation of EAAT with reference to AD pathogenesis. While 
the above studies point to a reduction in EAAT2 in human AD, this is contested in other studies 
(58). As technology advances and the ability to monitor EAAT function through positron 
emission tomography becomes available (59), the regulation of EAAT2 in AD may become 
clearer.  
The development of sophisticated gene profiling techniques (Gene Chip arrays, RNA 
sequencing) has allowed large-scale quantitative gene analysis of AD human tissue and age 
matched controls. These techniques have revealed decreased EAAT2 mRNA levels in 
hippocampal tissue taken from stage III-VI patients. Furthermore, the same study highlighted 
a localisation that correlated with neurofibrillary tangles and Aβ positive plaques (55). The idea 
that changes in EAAT2 expression reflect disease progression is further supported by work 
using human hippocampal membrane preparations, detailing that the progression from mild 
cognitive impairment (MCI) to AD involves significant decreases in EAAT2 protein levels (60). 
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Analysis of prefrontal cortex samples from Harvard Brain Tissue Resource Centre showed 
that AD tissues show greatly reduced protein and mRNA expression of EAAT2 (54). 
Fewer reports have looked at EAAT1 expression in human AD post-mortem tissue and present 
contrasting findings. Protein and mRNA levels of EAAT1 in the frontal cortex are reportedly 
unchanged between AD groups and control (56). EAAT1 mRNA and protein has been shown 
to be reduced in prefrontal cortex from AD samples (54). Hippocampal regions also show 
pronounced loss of EAAT1 mRNA, particularly in later stage AD (55). Likewise, gene chip 
arrays and RT-PCR showed EAAT1 to be significantly reduced in the hippocampus and middle 
frontal gyrus (12% and 18% respectively) of AD brains. Interestingly,  EAAT1, normally 
expressed exclusively in astrocytes, has been shown to co-localize with tau in cortical 
pyramidal neurons of AD human tissues, suggesting an intriguing potential link between 
aberrant EAAT1 expression and AD pathology (61). 
Relevance to Alzheimer’s disease 
Glutamate is the major excitatory neurotransmitter in the central nervous system, and 
glutamatergic neurons are located in areas that are targeted by the AD pathological cascade 
(62,63). Disruption in glutamatergic signalling has been reported in both animal models of AD 
and people with dementia (62,64). Indeed a breakdown in glutamate homeostasis forms the 
basis of the ‘glutamatergic’ hypothesis in AD (65–67). It is also noteworthy that current 
symptomatic relief for AD is provided by memantine, a metabotropic glutamate receptor 
antagonist. Therefore the astrocyte-specific EAATs offer an intriguing therapeutic target (68–
70) for manipulating excessive glutamate levels as described in AD.  
Preclinical animal studies had highlighted the potential of the β-lactam antibiotic, ceftriaxone, 
to increase glutamate transport (71–74). However, this was not shown further in clinical trials 
investigating the efficacy of ceftriaxone for the neurodegenerative condition amyotrophic 
lateral sclerosis (ALS) (75). This has stimulated researchers to adopt new approaches in order 
to develop compounds that can activate EAAT protein expression at a translational level (76). 
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High throughput screening has revealed a number of compounds that act as EAAT2 activators 
in expression systems (71,76,77), thus acting to maintain extracellular glutamate 
concentration at physiological levels (in the low micromolar range). Most recently, a small 
molecule activator has been developed and characterised in animal models of 
neurodegeneration (78,79). In an ALS rodent model, the novel EAAT2 activator delayed motor 
function deficits and prolonged lifespan (78). How this will translate to treating humans remains 
to be seen, but any impact on disease onset would offer real hope to those at risk of developing 
AD or those in the early stages of the disease. Providing neuroprotection through modulation 
of EAAT function is therefore possible in animal models of disease; however the challenge will 
be translating these findings into a clinical application (80). Therefore, it remains to be seen 
which methods to target astrocytic glutamate transport will provide a safe and long term 
therapeutic benefit to all AD patients.  
2. SLC2A Glucose Transporters 
There are three families of glucose transporter proteins in mammals, each with multiple 
isoforms. These are the facilitative hexose transporters (GLUTs) of the SLC2 family, the 
sodium-glucose symporters (SGLTs) of the SLC5 family and the more recently characterised 
glucose transporters of the SLC50 family (SWEETs). The SLC2 family members; GLUT1 
(SLC2A1), GLUT2 (SLC2A2), GLUT3 (SLC2A3), GLUT4 (SLC2A4), GLUT6 (SLC2A6), 
GLUT8 (SLC2A8), GLUT9 (SLC2A9), GLUT10 (SLC2A10), GLUT11 (SLC2A11) and GLUT12 
(SLC2A12) have twelve transmembrane domains and transport glucose (see Figure 2B; 80). 
The SLC5 family mostly have fourteen transmembrane domains whose family members 
SGLT1 (SLC5A1), SGLT2 (SLC5A2), SGLT4 (SLC5A9), SGLT5 (SLC5A10) and SMIT1 
(SLC5A3) mediate active transport of glucose against its concentration gradient (82). 
Currently SWEET1 (SLC50A1) is the only reported SLC50 family member to be expressed in 
mammalian cells and is predicted to have seven transmembrane domains (83). Also relevant 
to the uptake of metabolic fuels for CNS metabolism are monocarboxylic acid transporters 
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(MCTs) of the SLC16 family allowing facilitative transport of lactate and pyruvate, namely 
MCT1 (SLC16A1), MCT2 (SLC16A7), MCT3 (SCL16A8) and MCT4 (SLC16A3) (84).  
The CNS, without its own significant fuel stores, is critically dependent on uptake of glucose 
from the bloodstream. The brain accounts for at least 20% of whole body glucose utilisation 
(85).  A summary of the cellular expression of the main glucose and MCTs in human and 
rodent CNS is provided by Nijland et al. (2014). The glucose transporter GLUT1 (SLC2A1) 
accounts for the majority of glucose entry into CNS tissue through brain vascular endothelial 
cells, although there is evidence that SGLTs can also contribute to this process (87). The main 
astrocytic glucose transporter is GLUT1, while neurons, by contrast, express mainly GLUT3 
which has a higher transport activity than GLUT1 (88). In addition, both astrocytes and 
neurons also express the insulin-regulated glucose transporter GLUT4 (88).  In relation to the 
MCTs, there is a cell specific pattern with astrocytes expressing MCT1 and MCT4 (89,90), 
while neurons express MCT2 which displays a higher substrate affinity than MCT1 (84). 
Neuronal function is absolutely dependent on supply of metabolic fuel, and to this end 
neuronal activation is efficiently coupled to energy utilisation and increased blood flow (85). 
Astrocytes represent an essential cellular link required for this neurovascular coupling and are 
therefore considered vital for the effective supply of blood and oxygen to meet the metabolic 
needs of neurons. Following glucose uptake, astrocytes can synthesise and store glycogen 
(91). Breakdown of glycogen in astrocytes is not able to protect the CNS from hypoxia, but 
can provide short term support to neurons when blood glucose availability does not meet 
demand (91). There are several models and some controversy about the metabolic substrate 
supplied by astrocytes. Magistretti and colleagues have proposed the glucose-lactate shuttle, 
whereby glucose taken up by astrocytes via GLUT1 is metabolised to lactate by glycolysis. 
Lactate then exits astrocytes via MCT1 and MCT4 and is taken up by neurons through MCT2, 
where it can be oxidised in the TCA pathway (Figure 3; 92,93). Other investigators suggest 
that glucose which is transported into the CNS through capillary endothelial cells avoids 
astrocytes entirely, and is in fact taken up directly into neurons via GLUT3 (94).  Other models 
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show glucose uptake via astrocytes at the capillary surface and released directly at synapses 
to be taken up by neurons (95).  
While debate surrounds astrocytic metabolic supply and demand, it is clear that brain glucose 
metabolism is decreased in preclinical patients (96), animal models of dementia (97)  and 
people with a diagnosis of AD (98). The molecular mechanisms behind this are poorly 
understood, although human AD studies highlight that astrocyte/endothelial GLUT1 (as well 
as neuronal GLUT3) levels are reduced in post-mortem AD brains (99,100). Loss of astrocyte 
glucose transporters (GLUT1) is also found in the arcAβ (expressing both the Swedish and 
Arctic APP mutations) transgenic animal model, with no detectable changes in neuronal 
glucose transporters (97).  
Relevance to Alzheimer’s disease 
Perturbed glucose metabolism is a contributing factor to the pathogenesis of AD (97,101,102). 
This disruption is reported to be one of the earliest features of AD, in that a reduction in brain 
glucose metabolism can be detected (103) and is used as a diagnostic tool (104). However a 
much more dynamic picture of glucose metabolism is emerging (105,106), with reference to 
timeline and impact of ageing.  
Recent work suggests that contribution of astrocytic glucose transporters is less significant 
than the importance of the vascular endothelial transporters (107). Further work also suggests 
that glial glucose transporters might not provide an appropriate target for preventing AD: as in 
drosophila AD models overexpression of GLUT1 in glia had no effect against Aβ induced 
neurotoxicity (108). However, this lack of effect could have been due to the genetic 
approaches used in this specific study and provides a cautionary tale in terms of interpreting 
genetic studies. In contrast, studies have highlighted a role for GLUT1 in memory formation 
and that GLUT1 induction is not mirrored by the neuronal GLUT3 protein (109). This indicates 
a level of selectivity for the astrocytic GLUT1 protein which seems to be task dependent. This 
remains to be therapeutically exploited. Therapeutic interventions seeking to enhance 
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astrocytic lactate transport may provide a more fruitful endeavour. MCT1 knockout mice show 
deficits in long term memory (109) and there is clear evidence that MCT1 and MCT4 are critical 
for memory formation in the hippocampus (110). The cancer field has developed some non-
specific MCT inhibitors (111) which are currently in clinical trials (AZD3965; 
http://www.clinicaltrials.gov/show/NCT01791595). There remains the potential for these 
inhibitors developed further in a neuroscience context. 
Metformin, the antidiabetic drug, has received a lot of attention with regards to its potential act 
as a novel therapeutic strategy in managing AD (112–114). This links into the emerging 
hypothesis that AD should be classed as a third type of diabetes (115,116). However, reports 
are conflicting as to its effectiveness as a therapeutic intervention and the risk of developing 
AD (117,118). This may underlie the fact that the extent of metformin’s molecular 
pharmacology is still under investigation (31,119,120). In relation to transporter activity, 
reports have highlighted that GLUT4 translocation could potentially underlie its regulation of 
glucose metabolism (121). Modulation of the GLUT4 transporter to elevate glucose levels to 
maintain physiological levels may provide a potential route for pharmacological intervention. 
However, given the dynamic regulation of this transporter via endogenous means (e.g. 
increasing energy demands; see (122)) using intrinsic mechanisms rather than exogenous 
applications may prove to be a better therapeutic strategy to target GLUT4 in the fight against 
AD (123). Longer term studies are needed to reveal the role of metformin administration in 
human subjects and the elevated risk, if any, of developing AD. Here there is a particular 
interest in the APOE-ε4 genotype given its known associated risk with AD (124).   
Astrocytes have a greater glycolytic capacity than their neuronal counterparts (125,126); 
indeed, this may contribute to the resilience against Aβ accumulation in contrast to the 
catastrophic neuronal loss (127). It is interesting that most transgenic rodent models fail to 
reproduce neuronal loss on the same scale as the human disease. This may indicate a 
species-specific expression of key metabolic enzymes, such as PDK1. This could lead to drug 
discovery programmes targeting these enzymes. However, this may be a short term protective 
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mechanism prior to symptom onset. The long-term potential of aerobic glycolysis to match the 
continual decline in glucose availability remains to be determined, however transporter activity 
can feed into this enhancement of astrocytic metabolism. For example, BDNF, which has 
received a lot of interest as an Alzheimer’s therapeutic target (128), has been shown to 
modulate the expression levels of GLUT3 with astrocyte transporter levels not determined 
(129). Furthermore, lactate can stimulate BDNF production in both human astrocytes and 
SHSY5Y cells in a time-dependent manner (130). Such studies highlight the importance of a 
therapeutic timeline in which to stimulate astrocytes to respond to the growing deficits in 
neuronal energy supply. 
There are some indirect interventions which may lead to improved glucose metabolism in AD. 
For example, a recent study has reported the use of a cannabinoid receptor type 2 agonist to 
enhance CNS glucose uptake (131). Interventions targeting β-adrenoceptors, which induce 
glucose uptake and storage and breakdown of glycogen in astrocytes, also have promise to 
improve the supply of glucose and lactate to neurons and modify disease progression 
(132,133). 
Multiple mechanisms, some restricted to astrocytes, can therefore influence brain metabolism. 
The challenge is to generate specific compounds that target these proteins; which may be 
through direct interaction with the astrocyte transporters or indirectly through modulation of 
cellular processes that impact of energy metabolism. What is clear is that astrocytes are key 
to the regulation of brain glucose metabolism and should be considered as part of a solution 
in redressing the energy deficit in neurodegeneration. 
3. SLC6 Neurotransmitter Transporters 
The neurotransmitter family (SL6) incorporates GABA, glycine, monoamine and neutral amino 
acid transporters. Neurotransmitter transport is Na+ and Cl- dependent, with the stoichiometry 
of ionic coupling being subfamily specific (134). The predicted topology of twelve 
transmembrane domains (see Figure 2B; 108) has been confirmed from crystal structure 
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studies using a prokaryote homologue, the leucine transporter (LeuT; (136)). These 
transporters are expressed throughout the CNS and are critical in maintaining physiological 
levels of neurotransmitters making them an interesting target for therapeutic intervention. 
GABA and glycine are vital inhibitory neurotransmitters influencing information processing, 
network synchrony and neuronal plasticity. An imbalance in excitatory and inhibitory neuronal 
activity has been implicated in AD, with a focus on modulating excitation to reduce 
neurodegeneration associated with excess excitatory tone  (33). The ability of astrocytic GABA 
and glycine transporters to suppress excitation has previously been demonstrated (137,138). 
To date there has been limited research into these transporters and their involvement in AD.  
Astrocytes show a predominant expression of the GAT3 (SLC6A11) protein, with GAT2 
(SLC6A13) and BGT-1 (SLC6A12) also expressed but not exclusively in astrocytes (139). 
Disruption of GABAergic systems has been implicated in the pathogenesis of AD (140). Loss 
of GABAergic terminals has been reported in human AD brain (141), network imbalance in the 
hAPPJ20 transgenic model of AD has been linked to reduced GABAergic activity (142) and 
transplantation of GABAergic interneurons restores AD related cognitive decline in mice (143).  
The strongest evidence for a role of astrocytes has come from research by Wu et al., (2014), 
looking at both transgenic models of disease and human tissue. Using the 5xFAD model of 
disease (144) they reported both neuronal and astrocytic GABA modulation, high GABA 
content in astrocytes and upregulation of the α5 subunit of the GABAA receptor. Astrocyte 
enriched GAT3/4 (SLC6A11; human GAT3/mouse GAT4) was implicated in releasing excess 
GABA leading to elevated tonic inhibition of signalling in the dentate gyrus (Figure 3). GABA 
transporters can operate in either direction, either taking up or releasing GABA, in both 
physiological and pathological conditions (145).  
Wu et al., (2014) highlighted that modulation of GAT3/4 could be a novel AD therapy, although 
current pharmacological tools would need to be developed for this purpose. Furthermore, they 
suggest that increased astrocytic GABA content may provide a biomarker for AD; increases 
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in GABA occurred in line with development of Aβ deposition. Highlighting the need to replicate 
AD animal model studies in humans, Wu et al., (2014) also observed increased GABA content 
in human AD samples, giving further weight to the role of astrocytic GABA in AD. There are 
interesting links to the loss of GABAergic signalling with ageing and APoE4 expression 
(143,146), two known risk factors for AD. Whether this is an astrocyte-dependent process 
merits further investigation. It remains to be determined if GABAergic dysfunction is found in 
all forms of AD, which will impact on the drug development targeting the astrocytic GABA 
transporters.  
In comparison, glycine transport has so far received little attention in the field of AD. Astrocytes 
express the GlyT-1 (SLC6A9) transporter; although expression is not restricted to astrocytes. 
Furthermore there is conflicting evidence as regards the expression of GlyT-2 (SLC6A5) with 
early studies suggesting a neuronal specific isoform and later studies proposing a neuronal 
and astrocyte localisation (28,137,147); differences in cellular preparations may underlie these 
discrepancies. Importantly glycine is a co-agonist of the NMDA receptor which has been linked 
to AD pathology (148). A study by Timmer et al., (2014) indicated a decrease in the levels of 
glycine in an animal model of AD which they proposed may influence the glutamatergic system 
via NMDA receptors (149). Therefore, mechanisms to increase synaptic glycine levels could 
be exploited to restore NMDA signalling which is lost in AD. To this end, a GlyT-1 inhibitor 
(ASP2535) improved cognition in the scopolamine-induced model of AD, signalling the 
potential for targeting glycine transport (150). However, the failure of this model to replicate 
the progressive nature of the AD limits our interpretation (151). 
The serotonin transporter (SERT, SLC6A4), which facilitates transport of 5-hydroxytryptamine 
(5-HT, serotonin), has largely been perceived as neuronal specific (152). However studies 
have shown the expression of functional SERT in astrocytes (27,153,154). These studies have 
been carried out in a range of in vitro preparations, so the significance of SERT astrocytic 
expression in vivo remains unresolved. Increasing evidence highlights a role for 5-HT in AD 
pathogenesis; human studies indicate a loss of 5-HT (155) and changes in 5-HT receptor 
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levels (5-HT1A, 5-HT2A, 5-HT4 and 5-HT6) in AD brains (156–160).  A number of 5-HT6 
antagonists are currently in clinical trials as so-called cognitive enhancers (161,162). Their 
ability to improve cognition is linked to modulation of the cholinergic and glutamatergic 
signalling rather than alterations in 5-HT levels (163,164). Furthermore there is recent 
evidence that may suggest a role for SERT in AD pathology (165,166). Human data presents 
an interesting debate surrounding polymorphisms within the SLC6A4 gene, with studies 
reporting an association with the etiopathogenesis of AD (167–169) and others the contrary 
(170–172).  
Relevance to Alzheimer’s disease 
Disrupted neurotransmitter signalling has long been associated with AD pathology (65,173). 
While much of the research focuses on the cholinergic and glutamatergic pathways, recently 
scientists have proposed changes in a host of other neurotransmitters (174,175).  
Based on preclinical work, AD therapy would look to inhibit astrocytic GATs which would 
reduce tonic GABAergic inhibition and improve cognition. To date, GAT1 inhibitors have been 
developed for the treatment of epilepsy (e.g. tiagabine; (176)). In addition, a GAT2 inhibitor, 
EF1502, has been used in preclinical studies and showed additional anticonvulsant effects 
when administered with tiagabine (177,178). While we await clinical development of astrocyte 
specific GATs inhibitors, examining astrocyte GABAergic transport may provide both insight 
into potential biomarker validation (astrocyte GABA content) and the efficacy of targeting 
astrocytic GABA transporters in combatting AD pathology. 
While the contribution of astrocyte-mediated uptake of serotonin is not completely established, 
it is possible that they are targets for AD therapeutics. Given that both antagonists and 
agonists of 5-HT6 receptors are reported to improve cognition, it is unclear if activation or 
inhibition of astrocytic SERT activity would benefit AD patients. To this end, the ability to 
pharmacologically target astrocyte rather than  neuronal  SERT will be a challenge, based on 
previous reports (179). Overall, modulation of 5-HT transport has the potential to modulate 
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non-cognitive deficits in AD, such as depression; however, the use of selective 5-HT reuptake 
inhibitors in AD shows limited efficacy (180). Where alterations in 5-HT transport may provide 
benefits in frontotemporal dementia, where the serotoninergic system is disrupted, although 
studies to date have showed that effects are limited to the non-cognitive domains (181). 
Increasing NMDA mediated synaptic transmission via GlyT1 modulation may only serve to 
modulate disease progression at certain points in the pathogenesis of AD (i.e. prior to 
excitotoxic events; Figure 3). While this would not prevent the disease from developing, it may 
provide a disease-modifying treatment which would be a significant advance on the current 
symptomatic treatments available. However, it would not provide a long-term strategy to 
manage the disease as it progresses. This may highlight the need for a progressive strategy 
to tackle AD and finding the therapeutic window for different neurotransmitter targeted 
treatments and how to exploit them will be key to developing future therapeutic strategies. 
4. SLC3/SLC7 Heteromeric Amino Acid Transporters 
The cystine/Glu antiporter system xc– consists of two membrane spanning proteins: the light 
chain, XCT (SLC7A11) with twelve or fourteen transmembrane spanning domains that 
associates with the heavy chain protein 4F2hc (SLC3A2), also known as FRP (fusion 
regulatory protein) and CD98hc. 4F2hc has a single transmembrane domain (see Figure 2C; 
152). Together these proteins mediate the heteroexchange of cystine and glutamate with a 
stoichiometry of cystine:glutamate of 1:1 at the plasma membrane. The complex can operate 
in either direction, but is generally considered to import cystine and export glutamate from the 
cell (183,184).  
In the CNS, system xc- is predominantly expressed on glial cells, particularly astrocytes (185). 
Astrocytes are rich in glutathione compared to neurons, and release glutathione which can 
then be taken up by neurons (186).  This mechanism is considered to be one of the most 
important ways that astrocytes confer neuroprotective effects, through reducing neuronal 
susceptibility to oxidative stress, and it is system xc- which controls glutathione levels: 
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imported cystine is reduced intracellularly to cysteine, which is used in the synthesis of 
glutathione (GSH) (187). System xc- also mediates glutamate release from astrocytes (Figure 
3). The non-vesicular (calcium-independent) glutamate release from astrocytes via system xc- 
is sufficient to activate neuronal glutamate receptors in the CNS and therefore system xc- 
directly contributes to neuronal excitability and synaptic plasticity (184,188,189).  
Relevance to Alzheimer’s disease 
In relation to system xc- as a therapeutic target, most published work to date has focused on 
developing methods to inhibit system xc- as it has been identified as a key system in several 
cancers. For AD, upregulation of system xc- activity should be disease-modifying by 
increasing glutathione; however, conversely, increased system xc- activity may contribute to 
increased extracellular glutamate levels, potentially leading to excitotoxic neuronal death (see 
Section 1). To date, however, there are no studies characterising changes in CT, 4F2hc levels 
or xc- activity in AD or animal models of AD disease. Nonetheless, neuroprotective properties 
of ceftriaxone in an animal model of motor neuron disease have been attributed to its ability 
to induce XCT (190) but, paradoxically, deletion of XCT reduces symptoms in a transgenic 
mouse model of motor neuron disease (191). Therefore, it remains to be demonstrated if 
system xc- is a worthwhile target in the search for novel AD therapeutics.   
5. Na+.K+-ATPases 
The ubiquitous plasma membrane protein sodium-potassium ATPase (Na+.K+-ATPase), 
commonly known as the Na+ pump is classified as an enzyme (EC 3.6.3.9).  Na+.K+-ATPase 
is a primary active transporter transporting Na+ out of cells and K+ into cells against their 
concentration gradients with a stoichiometry of three Na+ exported for two K+ imported. Na+.K+-
ATPase is a heterodimer of α and β subunits. α subunits have ten transmembrane domains 
(see Figure 2D) and possess all the essential domains for ATP hydrolysis and ion transport 
with four family members identified in man: α1 (ATPA1), α2 (ATPA2), α3 (ATPA3), α4 
(ATPA4). Beta subunits are glycoproteins with a single transmembrane domain, of which there 
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are four family members in man: β1 (ATPB1), β2 (ATPB2), β3 (ATPB3), β4 (ATPB4) (192). 
There are also γ-subunits of the FXYD protein family which alter Na+.K+-ATPase activity 
through modulating affinity for Na+ and K+(193).  
Most focus on the Na+ pump in the nervous system has been on its role in maintaining Na+ 
and K+ gradients in neurons, with estimates that 60-70% of energy utilisation in the CNS is 
thought to provide ATP to power Na+.K+-ATPase. While neurons express the α3 isoform, 
astrocytes predominantly express the α2 and α1 isoforms together with β2 (194–196). The α2 
isoform has a higher Kd than the α1 isoform, suggesting that it is most important in astrocytes 
at times of high Na+ load, for example following neuronal activity (Figure 3). In those 
circumstances, there is a need for astrocytes to take up large quantities of glutamate via 
EAATs (see section 1) with a concomitant uptake of Na+. Supporting a close association 
between EAAT and Na+.K+-ATPase function, there is a physical interaction between the 
Na+.K+-ATPase α2 subunit and the major astrocyte SLC1A/EAATs: GLT-1 and GLAST (197) 
and stimulation of glutamate uptake results in an up-regulation of Na+.K+-ATPase activity 
(198). Disruption of astrocyte Na+.K+-ATPase activity, as found in human ATP1A2 gene 
mutations, leads to both epileptic seizures and familial hemiplegic migraine: these two 
examples of neuronal hyperexcitability syndromes are likely a consequence of reduced ability 
of astrocytes to take up K+ (199).  Further supporting a role of astrocyte Na+.K+-ATPase in 
supporting neuronal function, heterozygous mice with reduced Na+.K+-ATPase α2 subunit 
(astrocytes) or α3 subunit (neurons) display impaired spatial learning (200). In addition, protein 
levels of the α2 subunit have been shown to increase following inhibitory avoidance learning 
(109). 
In post-mortem AD brain tissue, there is a marked decrease in Na+.K+-ATPase α subunits as 
determined by binding of the Na+.K+-ATPase inhibitor, ouabain (201).  Ouabain is a pan 
Na+.K+-ATPase inhibitor displaying differing affinities for the three alpha isoforms and 
therefore does not discriminate between neuronal and glial α isoforms (202). Other studies 
have shown decreased Na+.K+-ATPase activity and α subunits with a concomitant decrease 
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in α3 mRNA, but an increase in α1 mRNA, attributed to up-regulation of α1 mRNA rather than 
mRNA degradation in reactive astrocytes (203,204). Likewise, α3 subunit protein levels and 
Na+.K+-ATPase activity are reduced in a double transgenic (APP and PS-1) mouse model of 
AD (205). With reference to the glial isoforms, exogenous application of Aβ25-35 resulted in a 
decrease in α1 subunit protein levels (206). Most recently, the α3 neuronal specific Na+.K+-
ATPase isoform is a target for Aβ assemblies, presenting a potential novel therapeutic strategy 
(207).  
Relevance to Alzheimer’s disease  
Whether corresponding therapeutic opportunities exist to stimulate astrocyte Na+.K+-ATPase 
and confer neuroprotection is an open question. Alterations in Na+ and K+ concentrations have 
been reported in AD tissue (208), with some reports highlighting a two-fold increase in 
intracellular Na+ and a 15% increase in intracellular K+ (206). These concomitant increases in 
intracellular levels of both Na+ and K+ highlights that while changes in Na+.K+-ATPase activity 
may occur, they cannot contribute solely to the global changes reported in AD. It is clear, 
however, that individual elements of AD pathology including amyloid beta peptide and 
oxidative stress can modulate learning and memory through modulation of Na+.K+-ATPase 
activity (209–211). This has led to an increasing number of Na+.K+-ATPase modulators being 
proposed as AD therapeutics (211). Many of these are preclinical observations tested in 
expression systems that remain to be robustly tested, of note however is the observation that 
currently approved AD therapeutics rivastigmine and memantine have been reported to 
increase Na+.K+-ATPase activity (212,213). At a molecular level, phosphorylation of the 
neuronal isoform is dynamically regulated by PKC and calcineurin (214,215). It is likely that a 
similar phosphorylation switch occurs in astrocytes, however given differences in Ca2+ 
sensitivity between the isozymes (α1β1 shows insensitivity to Ca2+; (216,217)) Na+ may play 
a more prominent role here. This reinforces the suggestion that regulation of Na+ homeostasis 
is of greater importance than Ca2+ in astrocytes (218,219).  
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6. ATP-binding cassette transporter family 
ATP binding cassette (ABC) transporters are membrane proteins which facilitate ATP 
dependent movement of a diverse array of substrates. Individual subunits are typically 
comprised of two six transmembrane-spanning domains with two nucleotide binding domains 
(see Figure 2E). This architecture permits two modes of transport; namely import and export. 
Five subfamilies (ABCA, ABCB, ABCC, ABCD and ABCG) allow for the transport of a diverse 
range of substrates, including many therapeutic drugs. Furthermore, various isoforms within 
the subfamilies enhance both the cellular and substrate specificity.  
ABCA transporters (ABCA1-13) have been shown to regulate lipid transport and gene 
expression data highlights that human astrocytes express ABCA1-3 at the mRNA level (220). 
There is however contrasting evidence at the protein level (221,222). More recently, reports 
have detected expression of ABCA5 in astrocytes although to a lesser extent than neuronal 
expression (223). This is of interest given the observation that the ABCA5 transporter has 
been linked to APP processing in vitro. This modulation of APP processing resulted in a 
reduction of the Aβ1-40 and Aβ1-42 variants (223). While the role of the astrocytic ABCA5 in Aβ 
generation remains to be determined, it is clear that transporter function can be regulated by 
key elements of AD pathology. Further evidence is needed as to the nature of the astrocyte 
ABCA transporters with reference to their expression, at both the mRNA and protein level and 
to their functional activity. For example, ABCA7 has been strongly implicated in APP 
processing, Aβ generation and the onset of dementia (224,225). However, the individual 
cellular role(s) of ABCA7 remains unresolved, and this is key given its widespread distribution 
(220,225). This shortfall in our understanding currently limits a critical appraisal of the role 
these astrocytic transporters may play in revealing a novel strategy to better manage AD 
pathology. 
P-glycoprotein 1 (PGP,MDR1, ABCB1) is highly expressed in the blood brain barrier, with 
protein detected in both the endothelial component and astrocytes (226). Therefore these 
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transporters have a key role in the elimination of Aβ from the brain, which is believed to be 
dysfunctional in late onset AD (227). Interestingly, when overexpressed in cancer cells, P-
glycoprotein 1 confers multidrug resistance through its export of cytotoxic messengers (228). 
In vitro evidence suggests that Aβ can act as a substrate for the transporters, and blockade 
of P-glycoprotein transport elevates extracellular levels of Aβ in a time dependent manner 
(229,230). Animal models of AD (3xTg and Tg2576) have revealed a link between both P-
glycoprotein 1 expression and activity in relation to disease progression (231,232). This 
evidence suggests that accumulation of the toxic form of Aβ can lead to downregulation of the 
P-glycoprotein 1 transporter. This correlates with human studies that reported elevated levels 
of Aβ and decreases in P-glycoprotein 1 levels (233,234). The relative contributions to Aβ 
clearance from capillaries and astrocytes remains to be fully understood. 
Multidrug resistance proteins (Mrps1-9) are members of the ABCC subfamily of the ABC 
transporters. Mrps are export pumps that use ATP to facilitate the efflux of organic cations 
(235). Regarding astrocyte expression, Mrp1 protein has been reported in rodent and human 
astrocytes (226,236); Mrp2 at the mRNA and protein level is lacking in astrocytes (237); Mrp3-
5 have been reported at both the mRNA level and protein levels in various astrocyte 
preparations (237,238). Evidence in the literature supports a role of Mrp1 in AD; however, this 
is not conclusive. For example, oxidative modifications of Mrp1 have been shown in AD brain, 
with lipid peroxidation a contributing factor (239). It remains to be see if this is a consequence 
of the disease process or a contributing factor.  
Relevance to Alzheimer’s disease 
There is a wealth of evidence that links lipid metabolism and AD (240,241) and this highlights 
the potential to target ABCA transporters given their role in cholesterol metabolism (222). This 
is pertinent for AD, given the genetic links to APOE-ε4 which is predominantly synthesised 
within astrocytes (242). While activation of the ABCA transporters can be achieved via 
agonists of the retinoid X receptor system (e.g. bexarotene), numerous other cellular proteins 
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are targeted by this system and therefore this limits the selectivity of agonists (243). This led 
to the discovery of an ABCA1 agonist that increased transporter activity, with a subsequent 
rise in cholesterol efflux (244). The use of a small molecule ABCA1 agonist (CS-6253) has 
produced some interesting results both in vitro and in vivo. In vivo studies highlight that 
injection of the CS-6253 peptide can restore cognitive deficits in APOE transgenic mice (245), 
and the peptide can modulate both central and peripheral lipid metabolism (246). This gives a 
clear indication that ABCA1 transporters can reverse cognitive decline, through modulation of 
ApoE4. While work remains to be done to look at the specific signalling cascades involved, 
the preliminary results are promising. It would be of interest to see whether the activation of 
astrocytic ABCA1 contributed to these effects. This could be achieved using astrocyte-directed 
genetic strategies to selectively knock out ABCA1 in astrocytes. 
Mrps alongside P-glycoprotein-1 are of interest from an AD perspective given their expression 
in the cellular constituents of the blood brain barrier (BBB; (247)). Thus, they may provide a 
route by which to enhance toxic Aβ clearance from the brain or indeed to facilitate transfer of 
a therapeutic agent into the brain. Aβ clearance is a subject of growing interest, albeit 
secondary to Aβ formation (248,249). Enhancing transporter mediator clearance of Aβ with a 
view to redressing the Aβ balance in the brain would be a therapeutic strategy worth pursuing. 
In support of this in vivo evidence highlights the upregulation of the P-glycoprotein transporters 
via pharmacological activation of the nuclear receptor pregnane X receptor (232). The diverse 
range of substrates for these transporters should facilitate drug discovery programmes to 
generate preclinical compounds of interest to the AD research community. Conversely, this 
may prevent the development of selective tools and another approach may be needed. One 
such strategy could explore transporter protein modification to alter the kinetics of Aβ efflux 
via the P-glycoprotein transporter. This type of strategy will be aided by the use of positron 
emission tomography (PET) studies, which can reveal P-glycoprotein transport kinetics in vivo 
(250,251). 
 
25 
 
Future perspectives 
Our knowledge of the roles astrocytes play in both physiology and pathology has increased 
greatly in the last decade and they are now seen as pivotal parts of the complex cellular 
network that maintain CNS function. As such, they are becoming of interest in 
neurodegenerative research (252). Neurological disorders such as AD are difficult to combat, 
although recent clinical trials with the anti-amyloid antibodies, Solanezumab (Eli Lilly) and 
Aducanamab (Biogen), may provide some hope (253,254). Given the lack of success for novel 
therapies targeting neuronal entities, it is perhaps surprising that to date few astrocyte targets 
have been identified. Advances in technology have increased our understanding of astrocytes 
and their interactions (255), which is still limited by poor astrocyte-specific markers which lack 
the robust nature of neuronal markers (5). The publication of the astrocytic transcriptome (24) 
revealed potential new cellular biomarkers that provide tools for generating specific 
therapeutic approaches to target astrocytes for the purpose of reducing neurodegeneration in 
AD.  
One challenge that still remains is understanding the heterogeneity of the astrocyte population 
(256) and being able to replicate this in experimental models. This may in part be overcome 
by the development of induced pluripotent stem cell (iPSC) technology. Again here, neuronal 
research has led the way and there is now an extensive research literature using this 
technology to further our understanding of neuronal cell death in AD (257–260). The ability to 
develop patient-derived cell lines gives researchers the opportunity to study disease pathology 
directly. In recent years investigators have developed methods to derive and maintain 
astrocytes from patient iPSCs (261–263). The question as to whether these cells truly 
represent functioning astrocytes in aged human brains remains to be answered (264). 
However initial studies have provided interesting insights into neurodegenerative diseases. 
Studies in AD-derived astrocytes are undoubtedly underway and we await the findings with 
interest.  
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Using these tools will unravel the complex role of astrocyte transporters at both a cellular and 
network level. The interplay between individual astrocyte transporters is evident (e.g. Na+.K+-
ATPase and SLC1A2/SLC1A3) and dysregulation of one set of transporters will impact on the 
functionality of other associated transporters (Figure 3). The challenge will be to dissect the 
timeline of this dysregulation to pinpoint molecular targets and their role in AD pathology. Many 
astrocyte proteins are intimately involved in the pathology of a disease which leads to neuronal 
cell death. Understanding if this dysregulation in transporter function occurs pre-
symptomatically, and the preliminary research indicates that this is the case, will be key to 
determining a therapeutic strategy. This has been helped by a growing awareness of 
astrocytes and their biology in the last decade. The purpose of this review was to highlight 
changes in select astrocytic transporter families and in doing so highlight a host of potential 
targets for AD. These targets can be classified accordingly to biological research themes 
which cover key areas not only for AD research but neuroscience research in general (Figure 
4). For these targets to become a realisation in terms of clinical products will require further 
research efforts in translatable neuroscience with direct clinical applications, allowing us to 
cross the ‘valley of death’ in drug discovery to provide much needed therapies for tackling AD.   
Encouragingly some drugs target some transporters highlighted in this review (e.g. EF1502; 
Section 3), but with a lack of selectivity for astrocytic isoforms it will hopefully be the next 
generation of compounds that target astrocyte specific transporters. Preclinical strategies here 
could use chemogenetic delivery systems as described for selective targeting of astrocyte 
adenosine receptors (265). This allows for the modulation of target activity through delivery of 
a synthetic ligand and has distinct advantages over the invasive optogenetic approaches 
(266). While this chemogenetic approach works well for G-protein coupled receptors 
(GPCRs), it is unclear if this approach could yield positive results for transporter proteins which 
are not exclusively coupled in a similar fashion. Research into tailor-made delivery systems is 
on-going and with pharmaceutic companies waking up to the idea of using the so called 
‘support cells’ to provide patient benefit (e.g. Astrocyte Pharmaceuticals), it will hopefully not 
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be long before astrocyte-targeting drugs are being considered as viable therapeutic strategies 
to combat complex neurological conditions, including AD. 
Figures/Table:  
Figure 1. A timeline of astrocyte involvement in AD pathology. A schematic 
representation of how astrocytes are believed to be involved in the pathogenesis of AD. (A) 
GFAP expression is routinely reported to increase in animal models of AD, with available 
human data indicating this may relate to physiological ageing other than AD specifically. 
However, the phenotypic change presented is consistent and highlights that this switch occurs 
before both amyloid deposition and neurodegeneration. This therefore highlights the 
importance of astrocytes in the early stages of disease and with it the potential to target them 
for patient benefit. (B) Schematic representation of the phenotypic changes reported in 
astrocytes from models of AD. (Left) A cartoon of a pre-symptomatic astrocyte showing 
elaborated processes and regulated volume. (Right) A cartoon of an astrocyte from an AD 
brain. Astrocyte atrophy is noted in several animal models of AD and can be defined by a 
variety of parameters including surface area. 
 
Table 1. An overview of the astrocyte transporters with proposed relevance to AD 
pathology. A review of the literature revealed several astrocytic transporters that have been 
implicated in AD pathology. Here we present an overview of the main protagonists, their 
reported involvement and models used to present lines of evidence, as discussed in the text. 
Where multiple substrates exist the predominant one is mention here. (TgAD= transgenic 
animal model). *it is unclear as to the contribution of astrocyte SERT to brain physiology; 
therefore, these observations may reflect neuronal SERT. #it is unclear the role of astrocyte 
ABCA7, expression levels are observed within all cells of the brain with microglia showing 
higher levels in comparison to neurones and astrocytes. 
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Figure 2. Topology of the astrocytic transporters. A schematic representation of the 
topology of astrocyte transporters. The transporters illustrated here highlight the diversity 
amongst the transporter families. (A) SLC1 transporter is shown regarding Section 1; (B) 
SLC2, 6 and 16 are used to illustrate Sections 2 and 3; (C) A SLC7/SLC3 heterodimeric 
complex is shown to illustrate Section 4; (D) EC 3.6.3.9 is shown to highlight the interplay 
between α, β and γ subunits to make a functional transporter. This is highlighted in Section 5; 
(E) MDR1 is shown as an illustration of the ATP-binding cassette transporter family. This 
family is discussed in Section 6. 
 
Figure 3. Astrocyte transporters coupled to AD signalling cascades. 1) EAAT2 transports 
glutamate from the synapse into the cytosol using ionic currents generated from primary active 
transporters which breakdown ATP. Therapeutically increasing the activity of this transporter 
may reduce glutamate-induced excitotoxicity evident in Alzheimer’s disease (AD). 2) 
Increasing GLUT1 levels or transporter activity could increase astrocyte glycolysis, improving 
the supply of lactate to neurons. Lactate can be taken up by neurons through MCT1 
transporters. 3) GAT3 inhibition could limit GABA release from reactive astrocytes, preventing 
long term deficits in neuronal activity. Targeting reactive astrocytes this way could increase 
neuronal activity in AD. GlyT-1 transporter inhibition may potentiate NMDA signalling by 
increasing the bioavailability of glycine at the synapse. Glycine is a co-agonist of the NMDA 
receptor and could act to modulate glutamatergic neurotransmission. 4) Glutathione (GSH) is 
the predominant antioxidant in astrocytes and is depleted in AD brains. Increasing cystine 
transport, via modulation of System xc-, could boost GSH antioxidant capacity. 5) Targeting 
Na+/K+ ATPase could have mixed effects. Inhibition could decrease sodium efflux from 
astrocytes but dampen neuronal activity. Conversely, activation would stimulate neuronal 
activity through increasing synaptic Na+ concentration but delay repolarisation via increased 
K+ influx. Furthermore, due to the interaction between Na+/K+ ATPase and EAAT2, targeting 
this pump may impact glutamate uptake dynamics (numbers refer to the relevant sections 
within the text). 
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Figure 4. Schematic of therapeutic opportunities for targeting astrocytes in AD. As 
outlined within the review various aspects of astrocyte physiology/pathology contribute to 
neurological disorders. Three specific areas are highlighted as indicated above with the 
molecular targets also listed. More detail about the specific transporters can be found in the 
relevant sections of the review. 
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